The strategic-level alliance will see UK-headquartered Exscientia take the 15 projects from target identification, drug design and lead optimisation, with Sanofi taking over at the preclinical ...

Exscientia also has a really substantial collaboration [oncology and immunology/inflammation, up to $5.2 billion, launched in 2022] with Sanofi. What’s most exciting is, those are all future ...

The strategic-level alliance will see UK-headquartered Exscientia take the 15 projects from target identification, drug design and lead optimisation, with Sanofi taking over at the preclinical ...

On the stock that's thought to be Exscientia Plc (NASDAQ:EXAI), Green commented: “… a short while ago the French drug giant Sanofi entered into a $283 million partnership with the company. But now ...

On the stock that’s thought to be Exscientia Plc (NASDAQ:EXAI), Green commented: “… a short while ago the French drug giant Sanofi entered into a $283 million partnership with the company.

Exscientia and Recursion have four of the lighthouse ‘techbio–biotech’ partnerships in this space: Sanofi, Roche/Genentech, Merck & Co. and Bayer. And when you look at the totality of the ...

Chris Gibson, PhD, Recursion’s co-founder and CEO, discusses exclusively with GEN Edge his company’s ambitious plans to ...

On the stock that’s thought to be Exscientia Plc (NASDAQ:EXAI), Green commented: “… a short while ago the French drug giant Sanofi entered into a $283 million partnership with the company.

“Exscientia’s precision chemistry tools and capabilities ... It plans to collaborate with top global firms including Roche-Genentech, Sanofi, Bayer, and Merck KGaA. There’s also the potential for ...

Sanofi has made a late entry to the radioligand party, paying 100 million euros ($110 million) upfront for global rights to a neuroendocrine tumor treatment that is nearing a filing for approval.

Sanofi is following several of its big pharma industry peers into radiopharmaceuticals, striking a deal for a clinical-stage therapy now in discussion for a regulatory submission as a treatment ...